Nancy Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nancy Kim has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Gemma McErlean
School of Nursing and Midwifery Faculty of Health University of Technology Sydney (UTS) Sydney Australia
2 shared publications - Ian Kerridge
The University of Sydney, Sydney, Australia
2 shared publications Anne Elwell
Qualidigm, 100 Roscommon Drive, Middletown, Conn
1 shared publicationCat Burkat
Madison, Wisconsin
1 shared publicationChohreh Partovian
Center for Outcomes Research and Evaluation, Yale–New Haven Hospital New Haven Connecticut
1 shared publication- Dale Robert Meyer
Lions Eye Institute, Albany Medical Center, 1220 New Scotland Road, Slingerlands, NY 12159, USA
1 shared publication
Latest Publications
- Open Access
- 16 May 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (5) , 283
Healthcare Resource Use and Costs of Allogeneic Hematopoietic Stem Cell Transplantation Complications: A Scoping Review
Allogeneic hematopoietic stem cell transplant (allo-HSCT) is an expensive and resource intensive procedure. This study aims to review the literature pertaining to healthcare resource utilization (HRU) and costs associated with allo-HSCT complications. The review followed the Joanna Briggs Institute methodology for scoping reviews. The PubMed, EMBASE, and Health Business Elite were searched in addition to the grey literature. Eligibility criteria included studies that reported HRU and/or costs associated with adult (≥18 years) allo-HSCT. Studies were categorized according to complications of allo-HSCT including graft-versus-host disease (acute and chronic GVHD) and infections (fungal, cytomegalovirus, virus-associated hemorrhagic cystitis, and acute respiratory tract infection). Commonly reported HRU and cost measures were extracted, including those associated with the direct management of allo-HSCT complications and intensive care unit (ICU) admissions. Reported costs were standardized to 2022 United States Dollars. Patients who experienced GVHD or infection post-transplant had an overall greater HRU including higher rates of hospitalization, hospital readmission, ICU admission, and longer length of stay compared to those patients who did not. Patients with severe or refractory GVHD and/or infection following allo-HSCT required greater healthcare intervention. This scoping review synthesizes the current literature on HRU and costs associated with post allo-HSCT complications. Patients who experienced post allo-HSCT complications had higher HRU and incurred higher costs overall, noting the variability across studies in their clinical context, reporting of HRU, and cost measures.
- 16 May 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (5) , 283
Open AccessHealthcare Resource Use and Costs of Allogeneic Hematopoietic Stem Cell Transplantation Complications: A Scoping Review
Allogeneic hematopoietic stem cell transplant (allo-HSCT) is an expensive and resource intensive procedure. This study aims to review the literature pertaining to healthcare resource utilization (HRU) and costs associated with allo-HSCT complications. The review followed the Joanna Briggs Institute methodology for scoping reviews. The PubMed, EMBASE, and Health Business Elite were searched in addition to the grey literature. Eligibility criteria included studies that reported HRU and/or costs associated with adult (≥18 years) allo-HSCT. Studies were categorized according to complications of allo-HSCT including graft-versus-host disease (acute and chronic GVHD) and infections (fungal, cytomegalovirus, virus-associated hemorrhagic cystitis, and acute respiratory tract infection). Commonly reported HRU and cost measures were extracted, including those associated with the direct management of allo-HSCT complications and intensive care unit (ICU) admissions. Reported costs were standardized to 2022 United States Dollars. Patients who experienced GVHD or infection post-transplant had an overall greater HRU including higher rates of hospitalization, hospital readmission, ICU admission, and longer length of stay compared to those patients who did not. Patients with severe or refractory GVHD and/or infection following allo-HSCT required greater healthcare intervention. This scoping review synthesizes the current literature on HRU and costs associated with post allo-HSCT complications. Patients who experienced post allo-HSCT complications had higher HRU and incurred higher costs overall, noting the variability across studies in their clinical context, reporting of HRU, and cost measures.
- Open Access
- 7 February 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (5) , 542.e1-542.e29
Healthcare Resource Utilization and Cost Associated with Allogeneic Hematopoietic Stem Cell Transplantation: A Scoping Review
- 7 February 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (5) , 542.e1-542.e29
Open AccessHealthcare Resource Utilization and Cost Associated with Allogeneic Hematopoietic Stem Cell Transplantation: A Scoping Review
- Open Access
- 12 June 2013
- Published by Wiley in Journal of Hospital Medicine
- Vol. 8 (7) , 373-379
Spending more, doing more, or both? An alternative method for quantifying utilization during hospitalizations
BACKGROUND: Because relative value unit (RVU)‐based costs vary across hospitals, it is difficult to use them to compare hospital utilization.OBJECTIVE: To compare estimates of hospital utilization using RVU‐based costs and standardized costs.DESIGN: Retrospective cohort.SETTING AND PATIENTS: Years 2009 to 2010 heart failure hospitalizations in a large, detailed hospital billing database that contains an itemized log of costs incurred during hospitalization.INTERVENTION: We assigned every item in the database with a standardized cost that was consistent for that item across all hospitals.MEASUREMENTS: Standardized costs of hospitalization versus RVU‐based costs of hospitalization.RESULTS: We identified 234 hospitals with 165,647 heart failure hospitalizations. We observed variation in the RVU‐based cost for a uniform “basket of goods” (10th percentile cost $1,552; 90th percentile cost of $3,967). The interquartile ratio (Q75/Q25) of the RVU‐based costs of a hospitalization was 1.35 but fell to 1.26 after costs were standardized, suggesting that the use of standardized costs can reduce the “noise” due to differences in overhead and other fixed costs. Forty‐six (20%) hospitals had reported costs of hospitalizations exceeding standardized costs (indicating that reported costs inflated apparent utilization); 42 hospitals (17%) had reported costs that were less than standardized costs (indicating that reported costs underestimated utilization).CONCLUSIONS: Standardized costs are a novel method for comparing utilization across hospitals and reduce variation observed with RVU‐based costs. They have the potential to help hospitals understand how they use resources compared to their peers and will facilitate research comparing the effectiveness of higher and lower utilization. Journal of Hospital Medicine 2013;8:373–379. © 2013 Society of Hospital Medicine
- 12 June 2013
- Published by Wiley in Journal of Hospital Medicine
- Vol. 8 (7) , 373-379
Open AccessSpending more, doing more, or both? An alternative method for quantifying utilization during hospitalizations
BACKGROUND: Because relative value unit (RVU)‐based costs vary across hospitals, it is difficult to use them to compare hospital utilization.OBJECTIVE: To compare estimates of hospital utilization using RVU‐based costs and standardized costs.DESIGN: Retrospective cohort.SETTING AND PATIENTS: Years 2009 to 2010 heart failure hospitalizations in a large, detailed hospital billing database that contains an itemized log of costs incurred during hospitalization.INTERVENTION: We assigned every item in the database with a standardized cost that was consistent for that item across all hospitals.MEASUREMENTS: Standardized costs of hospitalization versus RVU‐based costs of hospitalization.RESULTS: We identified 234 hospitals with 165,647 heart failure hospitalizations. We observed variation in the RVU‐based cost for a uniform “basket of goods” (10th percentile cost $1,552; 90th percentile cost of $3,967). The interquartile ratio (Q75/Q25) of the RVU‐based costs of a hospitalization was 1.35 but fell to 1.26 after costs were standardized, suggesting that the use of standardized costs can reduce the “noise” due to differences in overhead and other fixed costs. Forty‐six (20%) hospitals had reported costs of hospitalizations exceeding standardized costs (indicating that reported costs inflated apparent utilization); 42 hospitals (17%) had reported costs that were less than standardized costs (indicating that reported costs underestimated utilization).CONCLUSIONS: Standardized costs are a novel method for comparing utilization across hospitals and reduce variation observed with RVU‐based costs. They have the potential to help hospitals understand how they use resources compared to their peers and will facilitate research comparing the effectiveness of higher and lower utilization. Journal of Hospital Medicine 2013;8:373–379. © 2013 Society of Hospital Medicine
- 1 February 2012
- Published by Elsevier in Ophthalmology
- Vol. 119 (2) , 425-425.e3
Streptococcal Orbital Abscesses
- 1 February 2012
- Published by Elsevier in Ophthalmology
- Vol. 119 (2) , 425-425.e3
Streptococcal Orbital Abscesses
- Open Access
- 1 August 2005
- Published by Elsevier in The American Journal of Medicine
- Vol. 118 (8) , 917-922
Primary care physicians, office-based practice, and the meaning of quality improvement
- 1 August 2005
- Published by Elsevier in The American Journal of Medicine
- Vol. 118 (8) , 917-922
Open AccessPrimary care physicians, office-based practice, and the meaning of quality improvement